您的当前位置:首页 > 行业数据 > 索乐匹尼布临床管线进展(截至2024年7月)
图片属性
图片格式:PNG 图片大小:179KB 图片尺寸:1830*381
同报告图片
 / 4
索乐匹尼布临床管线进展(截至2024年7月)_第1页
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
索乐匹尼布临床管线进展(截至2024年7月)_第2页
fCDlubTku70gfCDluILlnLrplIDllK7pop3vvIjnmb7kuIfnvo7lhYPvvIkgfCDlop7plb/njocgfCBDRVLlop7plb/njocgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS18LS0tLS0tLS0tLS0tfAp8IDIwMjIgfCA5My41ICAgICAgICAgICAgICAgICB8ICAgICAgICB8ICAgICAgICAgICAgfAp8IDIwMjMgfCAxMDcuNSAgICAgICAgICAgICAgICB8ICsxNSUgICB8ICsyMiUgICAgICAgfAp8IDIwMjQgfCAxMTUuMCAgICAgICAgICAgICAgICB8ICs3JSAgICB8ICs5JSAgICAgICAgfAoK6LWE5paZ5p2l5rqQ77ya5YWs5Y+45ryU56S65p2Q5paZ77yM5Lit5rOw6K+B5Yi456CU56m25omA
索乐匹尼布临床管线进展(截至2024年7月)_第3页
索乐匹尼布临床管线进展(截至2024年7月)_第4页
索乐匹尼布临床管线进展(截至2024年7月)_第5页
所属报告: 和黄医药-港股公司深度报告:小分子药物研发领军者创新驱动全球化-250401(25页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠